Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris

被引:57
作者
Frishman, WH
Glasser, S
Stone, P
Deedwania, PC
Johnson, M
Fakouhi, TD
机构
[1] New York Med Coll, Dept Med, Valhalla, NY 10595 USA
[2] Univ S Florida, Coll Med, Div Clin Pharmacol, Tampa, FL USA
[3] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA
[4] VA Med Ctr, Div Cardiol, Fresno, CA USA
[5] Pharmanet, Princeton, NJ USA
[6] GD Searle & Co, Skokie, IL 60077 USA
关键词
D O I
10.1016/S0002-9149(98)00904-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This multicenter, randomized, double-blind, parallel group, placebo lead-in, placebo-controlled study compared the antianginal and anti-ischemic effects of once-daily bedtime dosing of controlled-onset extended-release (COER-24) verapamil to a once-daily morning dosing of amlodipine +/- atenolol in patients with chronic stable angina. A total of 551 patients with exercise-induced myocardial ischemia and evidence of coronary artery disease were randomized to a 4-week, forced-dose titration treatment period with (1) COER-24 verapamil 240 mg titrated to 480 mg at bedtime (n = 173), (2) amlodipine 5 mg titrated to 10 mg/day (n = 149), (3) amlodipine 5 mg (titrated to 10 mg) plus atenolol 50 mg/day in the A.M. (n = 154), or (4) placebo (n = 75), Treadmill exercise tolerance testing (standard Bruce protocol), and 48-hour ambulatory electrocardiographic (Holter) monitoring were performed at the end of placebo lead-in and double-blind treatment. Each active treatment significantly improved symptom-limited exercise duration and time to moderate angina (p less than or equal to 0.01 vs placebo). For patients with baseline ischemia, amlodipine resulted in a statistically significant increase in total duration of ischemic episodes compared with placebo, whereas COER-24 verapamil and amlodipine plus atenolol resulted in statistically significant decreases compared with placebo and amlodipine. Heart rate at onset of ischemic episodes and ST product were also significantly increased with amlodipine (p <0.05) compared with either COER-24 or amlodipine plus atenolol, COER-24 and amlodipine alone or in combination with atenolol improved exercise capacity in patients with angina pectoris, COER-24 verapamil monotherapy or amlodipine plus atenolol combination therapy were more effective than amlodipine monotherapy in decreasing ambulatory myocardial ischemia, especially during the hours of 6 A.M. to 12 noon. (C) 1999 by Excerpta Medica, Inc.
引用
收藏
页码:507 / 514
页数:8
相关论文
共 14 条
[1]   SUBSETS OF AMBULATORY MYOCARDIAL-ISCHEMIA BASED ON HEART-RATE ACTIVITY - CIRCADIAN DISTRIBUTION AND RESPONSE TO ANTIISCHEMIC MEDICATION [J].
ANDREWS, TC ;
FENTON, T ;
TOYOSAKI, N ;
GLASSER, SP ;
YOUNG, PM ;
MACCALLUM, G ;
GIBSON, RS ;
SHOOK, TL ;
STONE, PH .
CIRCULATION, 1993, 88 (01) :92-100
[2]   CIRCADIAN VARIATIONS IN ISCHEMIC THRESHOLD AND THEIR RELATION TO THE OCCURRENCE OF ISCHEMIC EPISODES [J].
BENHORIN, J ;
BANAI, S ;
MORIEL, M ;
GAVISH, A ;
KEREN, A ;
STERN, S ;
TZIVONI, D .
CIRCULATION, 1993, 87 (03) :808-814
[3]   PLACEBO-CONTROLLED EVALUATION OF 3 DOSES OF A CONTROLLED-ONSET, EXTENDED-RELEASE FORMULATION OF VERAPAMIL IN THE TREATMENT OF STABLE ANGINA-PECTORIS [J].
CUTLER, NR ;
ANDERS, RJ ;
JHEE, SS ;
SRAMEK, JJ ;
AWAN, NA ;
BULTAS, J ;
LAHIRI, A ;
WOROSZYLSKA, M .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (16) :1102-1106
[4]   EFFECT OF AMLODIPINE, ATENOLOL AND THEIR COMBINATION ON MYOCARDIAL-ISCHEMIA DURING TREADMILL EXERCISE AND AMBULATORY MONITORING [J].
DAVIES, RF ;
HABIBI, H ;
KLINKE, WP ;
DESSAIN, P ;
NADEAU, C ;
PHANEUF, DC ;
LEPAGE, S ;
RAMAN, S ;
HERBERT, M ;
FORIS, K ;
LINDEN, W ;
BUTTARS, JA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 25 (03) :619-625
[5]   AMLODIPINE COMBINED WITH BETA-BLOCKADE FOR CHRONIC ANGINA - RESULTS OF A MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED DOUBLE-BLIND-STUDY [J].
DIBIANCO, R ;
SCHOOMAKER, FW ;
SINGH, JB ;
AWAN, NA ;
BENNETT, T ;
CANOSA, FL ;
KAWANISHI, DT ;
BAMRAH, VS ;
GLASSER, SP ;
BARRY, W .
CLINICAL CARDIOLOGY, 1992, 15 (07) :519-524
[6]   ANTIANGINAL DRUG-THERAPY FOR SILENT-MYOCARDIAL-ISCHEMIA [J].
FRISHMAN, WH ;
TEICHER, M .
AMERICAN HEART JOURNAL, 1987, 114 (01) :140-147
[7]  
FRISHMAN WH, 1998, HEART, P1583
[8]  
FRISHMAN WH, 1997, CARDIOVASCULAR PHARM, P1363
[9]   CIRCADIAN VARIATION OF MYOCARDIAL-ISCHEMIA IN PATIENTS WITH STABLE CORONARY-ARTERY DISEASE [J].
HAUSMANN, D ;
LICHTLEN, PR ;
NIKUTTA, P ;
WENZLAFF, P ;
DANIEL, WG .
CHRONOBIOLOGY INTERNATIONAL, 1991, 8 (05) :385-398
[10]   CIRCADIAN VARIATION OF TRANSIENT MYOCARDIAL-ISCHEMIA IN PATIENTS WITH CORONARY-ARTERY DISEASE [J].
ROCCO, MB ;
BARRY, J ;
CAMPBELL, S ;
NABEL, E ;
COOK, EF ;
GOLDMAN, L ;
SELWYN, AP .
CIRCULATION, 1987, 75 (02) :395-400